Remove companies alpine-immune-sciences-inc
article thumbnail

Skadden, Fenwick Lead $4.9B Alpine Immune Sciences Sale

Law 360 M&A

Biotechnology company Alpine Immune Sciences Inc., advised by Fenwick & West LLP, on Wednesday revealed that it has agreed to be bought by Vertex Pharmaceuticals Inc., led by Skadden Arps Slate Meagher & Flom LLP, in a $4.9 billion cash deal.

52
article thumbnail

Vertex Pharmaceutical's Move Beyond Its $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune

Benzinga

On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) agreed to acquire Alpine Immune Sciences Inc (NASDAQ: ALPN ) for $65 per share or approximately $4.9 The company recently added to its portfolio. billion in cash. Full story available on Benzinga.com

52